Back to top

What to Expect from CVS Health's Q3 Earnings

Read MoreHide Full Article

CVS Health (CVS - Free Report) saw its stock price jump 0.82% during regular trading hours Monday just one day before the company is set to report its third-quarter financial results. So, let’s see what to expect from CVS before the opening bell Tuesday.  

Overview

Shares of CVS had jumped throughout much of 2018 until its stock price sunk in October as part of the larger market downturn. Yet, October represents what is likely to be a major turning point in CVS’ history after the U.S. Department of Justice allowed the company to move forward with its proposed $70 billion acquisition of Aetna (AET - Free Report) .

CVS’ plan to buy the health insurer comes amid a shifting healthcare and pharmaceutical landscape, which includes Amazon’s (AMZN - Free Report) pharmaceutical expansion, Walgreens Boots’ (WBA - Free Report) Rite Aid (RAD - Free Report) deal, among others.

 

Q3 Outlook

CVS is expected to see its Q3 revenues climbed roughly 2.2% to reach $47.19 billion, based on our current Zacks Consensus Estimate. Meanwhile, at the bottom end of the income statement, CVS is projected to see its adjusted quarterly earnings surge 14% to hit $1.71 per share.

With that said, we still need to know how likely it is that CVS tops our quarterly earnings estimates. Luckily, we can turn to our exclusive non-financial metrics consensus estimate file to prepare for this.

The Zacks Consensus NFM file contains detailed estimate data for business segment metrics and non-financial metrics reported by companies. The data is acquired from digest and contributing broker models and includes the independent research of expert stock market analysts.

The Zacks Earnings ESP (Expected Surprise Prediction) compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter. The Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change.

This is done because, generally speaking, when an analyst posts an estimate right before an earnings release, it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago.

A positive Earnings ESP paired with a Zacks Rank #3 (Hold) or better ranking helps us feel confident about the potential for an earnings beat. In fact, our 10-year backtest has revealed that this methodology has accurately produced a positive surprise 70% of the time.

CVS is currently a Zacks Rank #3 (Hold) that sports “A” grades for both Value and Growth in our Style Scores system. CVS also currently holds an Earnings ESP of 0.00%. Unfortunately, this means our model is inconclusive. But it is worth noting that CVS had topped our quarterly earnings estimates for 10 straight quarters.

CVS is scheduled to release its Q3 2018 financial results before the market opens on Tuesday, November 6.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>



More from Zacks Stocks in the News

You May Like

Published in